Parkinson’s Disease

Understanding Parkinson's Disease

Parkinson’s disease is a progressive neurological disorder that affects movement. It commonly manifests through symptoms such as tremors, stiffness, slowness of movement, and difficulties with balance. This condition results from the gradual loss of dopamine-producing neurons in the brain.

Causes and Risk Factors

The exact cause of Parkinson’s disease is still unknown, but it is believed to involve a combination of genetic and environmental factors. Age is a significant risk factor, with most cases occurring in individuals over 60 years old. However, younger adults can also develop Parkinson’s disease due to genetic mutations or other factors.

Diagnosis and Early Detection

Diagnosing Parkinson’s disease involves a thorough clinical evaluation by a neurologist. Symptoms such as tremors, rigidity, and bradykinesia (slowness of movement) are assessed. Imaging tests like MRI and CT scans may be used to rule out other conditions and confirm the diagnosis. Early detection allows for the timely initiation of Parkinson’s disease treatment in Nevada, which can significantly improve outcomes.

Comprehensive Treatment Approaches

CNS Curative Technologies LLC stands at the forefront of research and development in cognitive enhancement, offering a breakthrough solutions for individuals managing Parkinson’s disease in older adults and Parkinson’s disease in younger adults, aids in symptom alleviation and supports cognitive health effectively. Leverage innovative intranasal nootropic formulation developments for enhancing quality of life and regain control over Parkinson’s symptoms.

The science and technology

NeuroClimax’s pre-clinical articles

– Ruben & Dagda, Raul & Mayorga, Emmanuel & Martinez, Bridget & Gallahue, Aine. (2022). Intranasal Administration of Forskolin and Noopept Reverses Parkinsonian Pathology in PINK1 Knockout Rats. International Journal of Molecular Sciences. 24. 690. 10.3390/ijms24010690
– Patented pharmaceutical technology against LewyBody dementia Parkinson’s disease US11612583B2: “Disease modifying methods for treating neurodegenerative diseases using nootropic agents” Raul Y Dagda, and Ruben K. Dagda
– National Science foundation I-corps awards to CNS Curative Technologies: Patients interviews for medical necessities for NeuroClimax development

https://www.nsf.gov/awardsearch/showAward?AWD_ID=2135052

4.- Vazquez-Mayorga E, Grigoruta M, Dagda R, Martinez B, Dagda RK. Intraperitoneal Administration of Forskolin Reverses Motor Symptoms and Loss of Midbrain Dopamine Neurons in PINK1 Knockout Rats. J Parkinson’s Dis. 2022;12(3):831-850. doi: 10.3233/JPD-213016. PMID34957950;

Third party studies of the ingredients

5.- PMCID: PMC9108570. Soman SK, Tingle D, Dagda RY, Torres M, Dagda M, Dagda RK. Cleaved PINK1 induces neuronal plasticity through PKA-mediated BDNF functional regulation. J Neurosci Res. 2021 Sep;99(9):2134-2155. doi: 10.1002/jnr.24854. Epub 2021 May 27. PMID: 34046942; PMCID: PMC8513622.

6.- Swain, M., Dagda, RY, Soman, S., Tapia, K., Dagda, RK.K. Brain-Derived Neurotrophic Factor protects neurons by stimulating mitochondrial function through Protein Kinase A, 2023, In-Press, Journal of Neurochemistry

7.- Seamon KB, Padgett W., Daly JW Forskolin unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc. Natl. Acad. Sci. USA. 1981;78:3363–3367. doi: 10.1073/pnas.78.6.3363.

8.- Owona BA, Zug C., Schluesener HJ, Zhang ZY Protective Effects of Forskolin on Behavioral Deficits and Neuropathological Changes in a Mouse Model of Cerebral Amyloidosis. J. Neuropathol. Exp. Neurol. 2016;75:618–627. doi: 10.1093/jnen/nlw043.

9.- Sangeetha S., Samanta MK, Manjunatha N., Tiwari S. Establishment of Pharmacokinetic Parameters for the Herbal Drug Containing Forskolin. J. Pharm. Res. 2011;4:2303–2306.